Wednesday, November 25, 2020 12:49 am

Regional News: Colorado’s first licensed cannabis R&D firm to study marijuana’s effect on Alzheimer’s disease

Formulation Technician Robyn Patrick cleans terpenes at a MedPharm lab in Denver on Wednesday, Feb. 26, 2020. MedPharm specializes in cannabis cultivation, extraction, and analysis. They’re planning to apply for Denver’s newly available research and development licenses to conduct clinical trials about the effects of THC on Alzheimer’s disease.
/ Hyoung Chang, The Denver Post

Tiney Ricciardi  | The Denver Post

A Denver-based company hopes to be the state’s first to study the effects of marijuana on Alzheimer’s disease, thanks to a newly available research and development license in the city.

MedPharm Holdings plans to apply for a Denver marijuana R&D license to test delta-9 tetrahydrocannabinol (THC), cannabidiol (CBD) and other cannabinoids’ effects on Alzheimer’s and dementia patients.

According to the Alzheimer’s Association, 5.8 million Americans have the disease, a degenerative brain disorder that affects a person’s memory and thinking skills. While there are drugs that help ease symptoms, they do not change the course of the disease.

Albert Gutierrez, CEO of MedPharm, sees Alzheimer’s as “one of the biggest things that’s plaguing our country now and in the future.” That’s why he’s excited about cannabis’ potential to treat it.


Share this!

Additional Articles

Rose Law Group pc values “outrageous client service.” We pride ourselves on hyper-responsiveness to our clients’ needs and an extraordinary record of success in achieving our clients’ goals. We know we get results and our list of outstanding clients speaks to the quality of our work.

News Categories